Aceclofenac

證據等級: L5

預測適應症: 10 個

Aceclofenac: From Musculoskeletal Pain to Inflammatory Spondylopathy

One-Sentence Summary

Aceclofenac is an oral non-steroidal anti-inflammatory drug (NSAID) of the phenylacetic acid class, widely established for symptomatic relief of pain and inflammation in musculoskeletal conditions including osteoarthritis and rheumatoid arthritis. The TxGNN model predicts it may be effective for Inflammatory Spondylopathy (encompassing ankylosing spondylitis and related axial spondyloarthropathies), with 3 clinical trials and 17 publications currently supporting this direction.

Quick Overview

Item	Content
Original Indication	Musculoskeletal pain and inflammatory arthropathy (OA, RA) — no Saudi Arabia regulatory approval on file
Predicted New Indication	Inflammatory Spondylopathy
TxGNN Prediction Score	99.63%
Evidence Level	L2
Saudi Arabia Market Status	Not marketed
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Aceclofenac is a phenylacetic acid-derived NSAID that inhibits both COX-1 and COX-2 enzymes, reducing prostaglandin synthesis to suppress pain and inflammation. Importantly, aceclofenac's anti-inflammatory profile extends beyond classical COX inhibition: it also downregulates pro-inflammatory cytokines including IL-1β and TNF-α — cytokines that drive the synovial and entheseal inflammation central to spondyloarthropathies. This dual mechanism makes it mechanistically well-suited for inflammatory spinal conditions.

Inflammatory spondylopathy — a category encompassing ankylosing spondylitis (AS), non-radiographic axial spondyloarthritis, and related disorders — is defined by exactly the prostaglandin- and cytokine-mediated inflammatory cascades that aceclofenac directly targets. NSAIDs are in fact the first-line pharmacological recommendation in international ASAS/EULAR guidelines for axial spondyloarthritis. Aceclofenac has been directly evaluated in RCTs involving AS patients since the mid-1990s, and comprehensive reviews consistently list AS alongside OA and RA as established indications.

The high TxGNN prediction score (99.63%) therefore reflects not a speculative leap, but a documented pharmacological relationship that simply lacks a formal Saudi Arabia (SFDA) registration. The primary open question is whether existing RCT evidence (predominantly from the 1990s) meets current regulatory standards, and how aceclofenac positions against more recently approved agents such as etoricoxib and celecoxib in this indication.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00647517	Phase 4	Completed	60	Pilot RCT evaluating tramadol/APAP add-on to COX-2 NSAID background therapy in patients with ankylosing spondylitis and rheumatoid arthritis (Taiwan). Confirms NSAIDs as backbone therapy in inflammatory spondylitis; BASDAI >3 used as disease activity threshold for enrollment.
NCT02883569	N/A	Completed	1102	Comparative effectiveness study of surgical vs. non-surgical treatment for low back pain from herniated intervertebral disc and spinal stenosis. Provides broad context on pharmacological management pathways for spinal disorders; aceclofenac role not specified.
NCT05164198	Phase 4	Unknown	448	Multicenter prospective trial examining standard-dose vs. reduced-dose TNF inhibitor in stable AS patients. NSAIDs likely used as background co-medication; aceclofenac is not the primary investigational agent.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
8823692	1996	RCT	The Journal of Rheumatology	3-month multicenter double-blind trial: aceclofenac 100 mg BID vs. tenoxicam 20 mg QD in active AS patients. Aceclofenac demonstrated equivalent efficacy and safety, establishing direct RCT evidence in inflammatory spondylopathy.
8823693	1996	RCT	The Journal of Rheumatology	Multicenter controlled trial of aceclofenac efficacy and tolerability specifically in active AS; confirmed therapeutic benefit and acceptable tolerability profile compared to indomethacin.
34876850	2021	Systematic Review	Journal of Pain Research	Most recent comprehensive review of aceclofenac analgesic and anti-inflammatory effects across musculoskeletal disorders including LBP, scapulohumeral periarthritis, OA, RA, and AS. Concludes aceclofenac is effective and generally well-tolerated.
15163279	2004	Review	Expert Opinion on Pharmacotherapy	Clinical review of aceclofenac in inflammatory pain management; reports >75 million patients treated worldwide; efficacy comparable to diclofenac, naproxen, and indomethacin across OA, RA, and AS settings.
11511027	2001	Review	Drugs	Reappraisal of aceclofenac in pain and rheumatic disease; covers effects on multiple inflammatory mediators and cartilage metabolism alongside head-to-head clinical comparison data with other NSAIDs.
8799688	1996	Pharmacodynamic Review	Drugs	Detailed pharmacodynamic profile; preclinical data suggest lower GI damage potential than diclofenac; double-blind trials confirm equivalent efficacy to ketoprofen, indomethacin, and diclofenac in RA, OA, and AS.
11548913	2001	Health Economics	PharmacoEconomics	Economic modelling of aceclofenac vs. other NSAIDs in OA, RA, and AS incorporating mild-to-moderate adverse event costs; supports a favourable overall cost-effectiveness profile.
22350497	2012	Review	Clinical Drug Investigation	Review of NSAID-induced gastropathy and PPI co-prescription strategy in OA, RA, and AS; directly relevant to designing a gastroprotection monitoring plan for aceclofenac use in spondylopathy.
10081315	1999	Clinical Overview	Revue Médicale de Liège	Clinical overview of aceclofenac (Biofenac) pharmacology and indications covering OA, RA, AS, and post-traumatic inflammation; standard oral dose confirmed at 100 mg twice daily in adults.
23192419	2013	RCT	Clinical Rheumatology	12-week double-blind placebo-controlled RCT of tramadol/acetaminophen add-on in AS (Taiwan, n=60); enrolled active AS per Modified New York Criteria with BASDAI >3. Confirms NSAID backbone role in AS management.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Two direct RCTs from 1996 demonstrate aceclofenac's efficacy in ankylosing spondylitis — the primary subtype within inflammatory spondylopathy — and multiple systematic reviews and narrative reviews consistently list this indication alongside OA and RA as established therapeutic territory. The drug's COX/cytokine inhibition mechanism aligns directly with the pathophysiology of inflammatory spondylopathy, making this a pharmacologically sound and evidence-supported candidate. The primary barrier is the absence of Saudi Arabia (SFDA) registration and the age of the foundational RCT data relative to current regulatory expectations.

To proceed, the following is needed:

Package insert review to obtain full warnings, contraindications, and drug interaction data (currently Blocking gap DG001)
Mechanism of action documentation from DrugBank (gap DG002) to complete the mechanistic rationale section
Safety monitoring plan addressing GI risk, renal function, and cardiovascular profile in line with current NSAID safety frameworks
Assessment of whether the 1996 RCT evidence base meets current SFDA regulatory registration requirements, or whether a bridging/new registration study is needed for the Saudi Arabia market
Competitive landscape review positioning aceclofenac against currently approved agents in Saudi Arabia for axial spondyloarthritis (e.g., etoricoxib, celecoxib, naproxen) to evaluate market differentiation potential
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.